|
½ÃÀ庸°í¼
¾ÏÀ» À§ÇÑ Á¦³×¸¯ ÀǾàǰ ½ÃÀå ºÐ¼®
Cancer Generics Market Analysis
|
RNCOS E-Services Pvt. Ltd. ¿¡¼ 2011³â 09¿ù ¿¡ ¹ßÇàÇÑ ¡¸¾ÏÀ» À§ÇÑ Á¦³×¸¯ ÀǾàǰ ½ÃÀå ºÐ¼®¡¹ º¸°í¼´Â 80 Pages·Î ±¸¼ºµÇ¾î, US $1,000 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.
¼¼°èÀÇ ¾ÏÀ» À§ÇÑ ÈĹßÀǾàǰ ½ÃÀåÀº 2010-2014³â CAGR(º¹ÇÕ¿¬°£¼ºÀå·ü) 27%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºí·Ï¹ö½ºÅÍ Ç×¾ÏÁ¦°¡ ÇâÈÄ ¸î³â°£ ƯÇã ½ÇÈ¿¸¦ ¸Â°Å³ª ¾àÁ¦ ºñ¿ë »ó½ÂÀ¸·Î ÀÎÇØ ºñ¿ë »è°¨À» À§ÇØ Á¦³×¸¯ ÀǾàǰ¿¡ Á¢±ÙÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁø Á¡ µîÀÌ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼´Â 2011³â±îÁö ¹ÌÈ 100¾ï ´Þ·¯ÀÇ Ç×¾ÏÁ¦°¡ ƯÇ㸦 ÁýÇàÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¼¼°èÀÇ ¾ÏÀ» À§ÇÑ Á¦³×¸¯ ÀǾàǰ(Cancer Generics) ½ÃÀå¿¡ ´ëÇØ Æ÷°ýÀûÀ¸·Î ºÐ¼®Çϰí, ½ÃÀå ÇöȲ°ú ¾÷°èÀÇ ¹ßÀü, °æÀï ȯ°æ, Á¦Ç° °³¹ß ÆÄÀÌÇÁ¶óÀÎ µ¿Çâ, Á¦Ç° ±â¼ú Çõ½Å µ¿Çâ¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. Á¦4Àå ½ÃÀå ¼ºÀå ÃËÁø¿äÀΰú ÀúÇØ¿äÀÎ - ¾Ï ¹ß»ý·üÀÇ »ó½Â
- ¾Ï Ä¡·áÁ¦ : ÁÖ¸ñ ¿µ¿ª
- Á¦ÈÞÀÇ Áõ°¡
- »õ·Î¿î Á¦³×¸¯ ÀǾàǰÀ» ã´Â ±â¾÷
Á¦5Àå ¾ÏÀ» À§ÇÑ Á¦³×¸¯ ÀǾàǰ : ½ÃÀå °³¿ä Á¦6Àå °æ±¸ Á¦³×¸¯ ÀǾàǰ - Arimidex (Anastrozole)
- Casodex (Bicalutamide)
- Aromasin (Exemestane)
- Femara (Letrozole)
- Leucovorin Calcium
- Megestrol Acetate
- Mercaptopurine
- Tarceva (Erlotinib)
- Tamoxifen
- Methotrexate
- Flutamide
- Hydrea (Hydroxyurea)
Á¦7Àå ÁÖÀÔ Á¦³×¸¯ ÀǾàǰ - Eligard (Leuprolide Acetate)
- Zoladex (Goserelin)
- Camptosar (Irinotecan)
- Zoledronic Acid
- Velcade (Bortezomib)
- Kytril (Granisetron)
- Taxotere (Docetaxel)
- Gemzar (Gemcitabine)
Á¦9Àå ÁÖ¿ä ±â¾÷ - Teva
- Hospira
- Ranbaxy
- Cipla
- Natco Pharma
- Dr. Reddy''s
LSH
|